Trump low-cost GLP-1 plan a likely boost for Eli Lilly, Novo Nordisk

Trump deal with GLP-1 drugmakers was based on lower prices in exchange for higher volume. Now companies will see higher volume without giving as many discounts.

The Trump administration's deal with GLP-1 drugmakers, including Eli Lilly and Novo Nordisk, was based on a premise of lower prices in exchange for higher sales volume. However, companies secured higher volume without the lower prices in some cases, with prices for GLP-1 drugs remaining around $500 to $700 per month. This deal affected the sales of drugs such as Trulicity and Ozempic, which are used to treat type 2 diabetes. The exact terms of the deal were not publicly disclosed, but it is known that the companies agreed to participate in a Medicare program.

This development directly affects the price that Medicare patients pay for GLP-1 drugs, as they may not see the expected discounts. Patients who rely on these medications may continue to pay around $40 to $70 per month out of pocket, depending on their insurance plan. The lack of discounts may also impact the overall cost of Medicare, potentially affecting the program's budget. This could have significant implications for the healthcare system as a whole.

The Trump administration's deal with GLP-1 drugmakers is part of a larger pattern of attempts to control drug prices. In the past, pharmaceutical companies have been criticized for high prices, and the government has sought to negotiate better deals. Insiders know that the pharmaceutical industry has significant lobbying power, which can influence policy decisions. The history of drug pricing negotiations and the complex relationships between pharmaceutical companies, government agencies, and healthcare providers provide context for this story.

In the coming weeks, investors will be watching Eli Lilly and Novo Nordisk's stock prices closely, as the companies are expected to report increased sales volume. A key date to watch is the release of the companies' quarterly earnings reports, which will provide more information on the impact of the deal. Surprisingly, some analysts predict that the lack of discounts may actually benefit the companies in the long run, as they will be able to maintain higher prices while still increasing sales volume.